Cytokeratin 7 and Cytokeratin 20 in Primary Urinary Bladder Carcinoma and Matched Lymph Node Metastasis

Abstract

Background.—Cytokeratin 7 (CK7) and cytokeratin 20 (CK20) are 2 types of intermediate filament protein. Expression of CK7 is seen in the majority of primary urinary bladder carcinomas. CK20 is restricted to superficial and occasional intermediate cells of the normal urothelium of the bladder. Aberrant CK20 expression has been documented in urothelial carcinoma and has proved useful as an ancillary diagnostic aid for urinary bladder tumor. Our hypothesis is that the pattern of CK7 and CK20 expression in metastatic urothelial carcinoma duplicates the expression of the same markers in the primary tumors. Therefore, immunohistochemical staining of metastatic tumors for these 2 markers may be helpful for differential diagnosis in ambiguous metastatic tumor deposits. Objective.—To determine the concordance of CK7 and CK20 expression in primary bladder urothelial carcinoma and the matched lymph node metastasis. Design.—We studied 26 patients with lymph node metastases who underwent radical cystectomy and bilateral lymphadenectomy for bladder carcinoma. Immunohistochemical staining for CK7 and CK20 was performed on formalin-fixed paraffin-embedded tissues containing primary cancers and lymph node metastases. Results.—In all cases, there was a concordant expression of CK20 in the primary cancer and its matched lymph node metastasis. Twelve cases (46%) showed positive CK20 immunoreactivity in the primary tumor and its matched lymph node metastases, whereas 14 cases (54%) were negative for CK20 in both the primary tumor and lymph node metastasis. All cases showed positive CK7 immunoreactivity in the primary cancers and matched lymph node metastases. Conclusions.—CK20 immunoreactivity is reliably observed in metastases from bladder cancer when the primary tumor expresses CK20.

Variation of Keratin 7 Expression and Other Phenotypic Characteristics of Independent Isolates of Cadmium Transformed Human Urothelial Cells (UROtsa)

“…The last goal of the study was to begin to characterize the expression of the keratin gene family because of the finding of squamous differentiation within the tumor heterotransplants derived from the Cd 2+ transformed cell lines. Keratin 7 was chosen for analysis since it is expressed in all epithelial cells of the normal urothelium and since its expression has been reported to be altered in bladder cancer , . The initial step in analysis was the histochemical staining for keratin 7 in the tumor heterotransplants generated from each of the 7 Cd 2+ transformed cell lines.…”

“…Phenotypic characterization included morphology and doubling times of the transformed cell lines, the histology of subcutaneous heterotransplants in nude mice, and the ability to colonize internal organ sites following intraperitoneal injection of the cells into nude mice. Keratin 7 expression was chosen for characterization of gene expression since it has been shown in humans to be expressed in cells of the normal urothelium and that the expression may be altered as a result of malignant transformation − . The expression of keratin 7 was also chosen for analysis because of the increased squamous differentiation noted in the tumors produced by the previous isolates of the Cd 2+ and As 3+ transformed UROtsa cells.…”

Moving translational mass spectrometry imaging towards transparent and reproducible data analyses: a case study of an urothelial cancer cohort analyzed in the Galaxy framework

“…Cytokeratine 7 is a type II intermediate filament protein that is present in most urothelial carcinomas [ 38 ]. IHC stainings were positive in 100% (14/14) of non-muscle infiltrating urothelial carcinomas and 82% (9/11) muscle-infiltrating urothelial carcinomas (Fig.…”

The value of BCL2 and CK20 expression in predicting behavioral patterns of bladder cancer, a cross sectional study

“…CK20 expression in the urothelium is restricted to superficial umbrella cells of the bladder even in the presence of severe inflammation [ 11 ]. Only malignancy induces a change in the expression pattern of CK20 [ 12 ]. The aim of this study was to investigate CK20 and BCL2 expression in patients with bladder tumor and its relationship with prognostic factors such as tumor stage and grade.…”